Match Document Document Title
US20110251121 USE OF CYSTEINE-RICH WHEY DERIVED PROTEIN IN PATIENTS RECEIVING CHEMOTHERAPY AND/OR RADIOTHERAPY TO IMPROVE PATIENT SURVIVAL  
A cysteine-rich undenatured whey-derived protein formulation did not interfere with the tumor-cytotoxic effects of chemotherapy and radiation therapy and did not have a negative effect on the...
US20120021971 Functional Food Product Comprising Heat Shock Protein or a Hydrolysate Thereof  
The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic...
US20140213510 USE OF PLEITROPHIN FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME  
The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of...
US20110028389 USE OF INFANT FORMULA WITH REDUCED PROTEIN CONTENT  
A method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-1) in the first few months of the life of an infant comprises administering to the 5 infant a...
US20150099695 C1q/TNF-RELATED PROTEIN-9 (CTRP9) AND USE IN PREVENTION AND TREATMENT OF METABOLIC DISORDERS  
Compositions and methods for treatment of obesity and/or Type II diabetes and related metabolic disorders are provided wherein the methods and treatments comprise an effective amount of an...
US20120129766 METHODS OF TREATING FGF21-ASSOCIATED DISORDERS  
The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods...
US20110256063 MEX3C REGULATION AND TARGET TO CONTROL OBESITY AND DIABETES  
MEX3C deficiency impairs the development of white and brown adipose tissue. Hence the present invention provides, among other things, a method of screening a candidate compound for activity in...
US20110256130 METHODS OF TREATING INFLAMMATORY DISORDERS  
Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of...
US20120219616 LIPOSOMAL REDUCED GLUTATHIONE AND l-ARGININE, INCLUDING WITH OTHER INGREDIENT(S), CAPABLE OF MULTIPATH ADMINISTRATION FOR REVERSAL AND PREVENTION OF OBESITY AND FOR MITOCHONDRIAL BIOGENESIS  
The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals...
US20110144006 PROTEIN COMPOSITION  
The invention relates to a protein composition which upon ingestion by a healthy person with a normal fasting insulin level between 3.0-8.0 μU/L increases the insulin level to at most 20.0 μU/L....
US20110263490 Diagnostic Methods and Combination Therapies Involving MC4R  
Methods and therapeutics are provided for treating metabolic disorders by activation of melanocortin signaling pathways. Generally, the methods and therapeutics can induce activation of...
US20140155316 FIBROBLAST GROWTH FACTOR 1 PROTEIN FRAGMENTS AND METHODS OF USE  
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and...
US20150080294 METHODS FOR PROMOTING LIPOLYSIS AND OXIDATION IN LIVER AND ADIPOSE TISSUE USING CATESTATIN  
The invention provides methods for treating obesity in a subject comprising administering an effective amount of catestatin (CST) or its equivalent to a subject afflicted with obesity so as to...
US20110091543 ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS  
Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed....
US20130216537 Methods of Treating Glucose Metabolism Disorders and Promoting Weight Loss  
Compositions and methods for treating individuals with a glucose metabolism disorder and methods for promoting weight loss in an individual are provided.
US20120282184 TREATMENT OF OBESITY  
A method for the prevention or treatment of a condition selected from type 2 diabetes, obesity and metabolic syndrome comprising activating a GITRL pathway. Methods for screening for substances to...
US20100184640 DOG DIABETES  
A method a method for diagnosing susceptibility to diabetes in a non-human animal, the method comprising: a) identifying whether or not a polymorphism as defined in Table 4 or a polymorphism which...
US20150065419 METHODS FOR TREATING METABOLIC DISORDERS USING FGF  
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.
US20140171361 METHODS FOR TREATING METABOLIC DISORDERS USING FGF  
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.
US20130116171 METHODS FOR TREATING METABOLIC DISORDERS USING FGF  
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.
US20130202681 LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE FOR MANAGEMENT OF CANCER AND DISRUPTION OF CANCER ENERGY CYCLES  
A method of treatment of cancer with a formulation of liposomally encapsulated glutathione, that is preferably used orally, increases the level of glutathione in tissues in order to prevent and...
US20110002994 METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT  
It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to...
US20110293725 CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME  
Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a...
US20140011737 COMPOSITIONS AND METHODS FOR REGULATING METABOLISM  
The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein.
US20150023960 Compositions and Methods of Use for Treating Metabolic Disorders  
Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
US20140213511 COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS  
Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
US20110212887 METHODS OF TREATING OBESITY USING ENTEROSTATIN  
The present invention provides methods of treating or preventing disorders or conditions associated with enterostatin deficiency by administering to a subject in need thereof an effective amount...
US20100316644 TRUNCATED ACTRIIB-FC FUSION PROTEINS  
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or...
US20140073562 NASAL DELIVERY  
A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a...
US20120207680 Methods of Identifying Candidate Compounds of the Human G Protein-Coupled Receptor, GPR50, as Modulators of Body Mass or Adiposity  
The present invention relates to methods of using a G protein-coupled receptor (GPCR) to screen one or more candidate compounds as a modulator of body mass or of adiposity or of percentage body...
US20110003013 METHOD OF INCREASING METABOLISM  
The present invention provides a method for increasing metabolism and/or energy expenditure in a subject, e.g., to treat or prevent obesity and/or a related condition and/or to reduce adiposity,...
US20150202259 TARGETED OESOPHAGEAL ADMINISTRATION OF ZN-ALPHA2-GLYCOPROTEINS (ZAG), METHODS AND FORMULATIONS THEREOF  
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to...
US20130065821 COMPOSITION FOR PREVENTING AND IMPROVING METABOLIC SYNDROME  
A method for improving blood HDL/LDL cholesterol ratio, reducing blood triglyceride level, reducing blood sugar level, and/or reducing body weight, that includes ingesting a composition containing...
US20120178672 Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis  
A nutritional composition and method of use that improves the net balance in skeletal muscle by targeting both the synthetic and breakdown processes. The disclosed composition provides for...
US20140107019 ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION  
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which...
US20130202646 COMPOSITIONS AND METHODS FOR MODULATING AUTOPHAGY  
In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a Tat-Atg5K130R (inhibitor of autophagy) and a Tat-Beclin 1...
US20120093883 METHOD OF TREATING AND PREVENTING NEURO-OLFACTORY TRIGGERED OR AGGRAVATED ILLNESSES OR RELATED CONDITIONS  
A method for treating at least one of neuro-olfactory triggered illnesses, and related conditions within a subject is provided. The method includes the steps of: a) providing a composition that...
US20100311649 SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS  
Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R)....
US20110177097 METHODS FOR MODULATING EXPRESSION OF CREB  
Methods are provided for modulating CREB by administering a CREB-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or...
US20110123521 METHODS FOR MODULATING EXPRESSION OF RBP4  
Methods are provided for modulating RBP4 by administering a RBP4-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or...
US20110130783 TREATMENT OF OBESITY AND RELATED DISORDERS  
This disclosure provides a method of treating obesity and related disorders through the administration of a composition comprising a neurotoxin and a mucosal permeabilizing agent. Methods for...
US20130210713 COLLAGEN POWDER  
The invention is directed to a method for preparing a collagen powder and to collagen powder that can be used for the preparation of a satiety inducing food product. The collagen powder of the...
US20140057837 METHODS AND COMPOSITIONS FOR THE "BROWNING" OF WHITE FAT  
Methods for increasing the amount of brown adipose tissue in a subject, of increasing the ratio of brown fat to white fat in a subject, or for effecting a change in white adipose tissue to become...
US20130324462 Method of Reducing The Effects of Chemotherapy Using Flagellin Related Polypeptides  
The use of flagellin and flagellin related polypeptides for reducing cancer treatment side effects in mammals is described.
US20110243923 ORGANIC COMPOUNDS  
The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7, 25-dihydroxycholesterol) (“7,25DHC”) and/or...
US20120004163 NUTRITIONAL COMPOSITION FOR INFANTS  
A nutritional composition for infants comprises a protein source, a lipid source and a carbohydrate source wherein the lipid source includes at least 16 wt % linoleic acid and at least 2 wt %...
US20130231277 CHIMERIC FGF21 PROTEINS WITH ENHANCED BINDING AFFINITY FOR BETA-KLOTHO FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, AND RELATED METABOLIC DISORDERS  
The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”)...
US20110245178 Exendin Fusion Proteins  
The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and...
US20140213512 Method of Treating or Ameliorating Type 1 Diabetes Using FGF21  
Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia,...
US20110200580 METHODS OF TREATMENT AND PREVENTION OF DIET-INDUCED OBESITY AND SEQUELAE THEREOF  
Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at...